SAMPLE_ID	ONCOTREE_CODE	LEVEL_1	LEVEL_2	LEVEL_3A	LEVEL_3B	LEVEL_4	LEVEL_R1	LEVEL_R2	LEVEL_R3	HIGHEST_LEVEL	LEVEL_Dx1	LEVEL_Dx2	LEVEL_Dx3	HIGHEST_DX_LEVEL	LEVEL_Px1	LEVEL_Px2	LEVEL_Px3	HIGHEST_PX_LEVEL	ONCOGENIC_MUTATIONS	#ONCOGENIC_MUTATIONS	#MUTATIONS_WITH_THERAPEUTIC_IMPLICATIONS	#MUTATIONS_WITH_DIAGNOSTIC_IMPLICATIONS	#MUTATIONS_WITH_PROGNOSTIC_IMPLICATIONS	#MUTATIONS
TCGA-05-4417-01	LUAD	Sotorasib(KRAS p.G12C);Sotorasib(KRAS p.G12C);Oncogenic(MET Amplification);Oncogenic(ERBB2 Amplification);Oncogenic( ALK-EML4);Oncogenic( TMPRSS2-ERG)	Brigatinib,Crizotinib,Lorlatinib,Ceritinib,Alectinib( ALK-EML4)	Adagrasib(KRAS p.G12C);Adagrasib(KRAS p.G12C);Crizotinib(MET Amplification)	Olaparib(ATM p.L2890R)	Trametinib,Cobimetinib,Binimetinib(KRAS p.G12C);Trametinib,Cobimetinib,Binimetinib(KRAS p.G12C);Trastuzumab,Trastuzumab+Carboplatin-Taxol Regimen,Trastuzumab+Pertuzumab,Lapatinib+Trastuzumab,Trastuzumab+Chemotherapy,Ado-Trastuzumab Emtansine,Pembrolizumab+Trastuzumab+Chemotherapy,Lapatinib+Capecitabine,Lapatinib+Letrozole,Trastuzumab+Tucatinib+Capecitabine,Trastuzumab Deruxtecan,Margetuximab+Chemotherapy(ERBB2 Amplification)			Erlotinib,Gefitinib,Osimertinib(MET Amplification)	LEVEL_1	25971939;26729443;21623265;Camidge et al. Abstract# 8001, ASCO 2014(http://meetinglibrary.asco.org/content/132030-144);30073261;30676858;18093943;17463250;Michels et al. JCO PO, 2018(https://ascopubs.org/doi/full/10.1200/PO.18.00210)(MET Amplification);16236738;29584549;30857956;27108243;23020162;30516102;33167735;19786658;17192538;31825569;31825192;Rugo et al. Abstract# 1000, ASCO 2019(https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1000)(ERBB2 Amplification);30280657;28475456;23724913;29596029;27432227;29074098;30413378;30892989;28126333;Chow et al. Abstract# 1478O, ESMO 2019(https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390);30215676;28586279;29668860( ALK-EML4)								ATM p.L2890R;KRAS p.G12C;KRAS p.G12C;TERT ;MYD88 M232T	5	6	0	0	13
TCGA-02-0033-01	BLLETV6RUNX1	Oncogenic(MET Amplification);Oncogenic(CDK4 Amplification);Oncogenic(CDK4 Amplification);Likely Oncogenic( MLL2-intragenic);Oncogenic( ETV6-RUNX1 fusion)								LEVEL_1		BLLETV6RUNX1( ETV6-RUNX1 fusion)			LEVEL_Dx1( ETV6-RUNX1 fusion)	7780150;8609706( ETV6-RUNX1 fusion)	B-Lymphoblastic Leukemia/Lymphoma( ETV6-RUNX1 fusion)		PIK3CA p.E542K;RB1 p.Q702*;TP53 p.R248Q;NF1 p.X1445_splice	4	4	0	0	10
TCGA-06-0155-01	GBM	Oncogenic( TMPRSS2-ERG)				GSK2636771,AZD8186(PTEN p.C136R)				LEVEL_1									EGFR p.H304Y;PTEN p.C136R	2	2	0	0	5
TCGA-AG-A002-01	READ	Pembrolizumab(Other Biomarkers TMB-H);Pembrolizumab(Other Biomarkers Tumor Mutational Burden-High)								LEVEL_1									Other Biomarkers TMB-H;Other Biomarkers Tumor Mutational Burden-High	2	2	0	0	2
TCGA-A6-2672-01	COAD	Nivolumab,Pembrolizumab,Ipilimumab+Nivolumab(Other Biomarkers MSI-H);Nivolumab,Pembrolizumab,Ipilimumab+Nivolumab(Other Biomarkers Microsatellite Instability-High)								LEVEL_1									Other Biomarkers MSI-H;Other Biomarkers Microsatellite Instability-High	2	2	0	0	2
TCGA-FAKE-01	AML	Gilteritinib,Midostaurin+High Dose Chemotherapy(FLT3 Internal tandem duplication)		Sorafenib,Crenolanib,Quizartinib(FLT3 Internal tandem duplication)						LEVEL_1		AML(FLT3 Internal tandem duplication)		LEVEL_Dx2	AML(FLT3 Internal tandem duplication)			LEVEL_Px1	EGFR vIII;FLT3 Internal tandem duplication;BRAF Kinase Domain Duplication;EGFR C-terminal domain	4	1	1	1	4
TCGA-FAKE-02	AML	Gilteritinib,Midostaurin+High Dose Chemotherapy(FLT3 ITD)		Sorafenib,Crenolanib,Quizartinib(FLT3 ITD)						LEVEL_1		AML(FLT3 ITD)		LEVEL_Dx2	AML(FLT3 ITD)			LEVEL_Px1	EGFR vV;FLT3 ITD;EGFR CTD	3	1	1	1	3
TCGA-FAKE-03	HDCN			Cobimetinib,Trametinib(BRAF KDD)						LEVEL_3A									BRAF KDD	1	1	0	0	1
